EAVE II shortlisted in HDR UK Annual Awards

The EAVE II project has been shortlisted for Health Data Research UK's Team of the Year Award.

We are happy to announce that the EAVE II project has been short-listed for Health Data Research UK's Annual Team of the Year Award. This award celebrates collaborative endeavours by groups of researchers, innovators, technologists, triallists and more working together within HDR UK and beyond. The results will be announced at HDR UK's 2022 Annual Scientific Conference on Wednesday 14 December. The event will run online from 9:30-17:00.

Read more about: HDR UK's Annual Awards

Read more about HDR UK's 2022 Annual Scientific Conference

The Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) project was initiated in 2020 to track COVID-19 and its effects across Scotland, and later the uptake, safety, effectiveness and waning of the COVID-19 vaccines.

Read more about EAVE II

The EAVE II team has been shortlisted for their inclusive and innovative leadership , with particular recognition being given to the project's collaboration with partners in the FioCruz institute in Brazil. Together, the teams have conducted powerful cross-country analyses of COVID-19 vaccine effectiveness and waning in both adults and adolescents aged 12-17.

The first study found that the protection offered by the Oxford-Astra Zeneca Covid-19 vaccine declines after three months of receiving two doses.

The second study into adolescents, showed that the protection provided by the Pfizer BioNTech vaccine against severe COVID-19 remained strong 98 days after the second dose, during the Omicron period. However, it also found that protection against symptomatic COVID-19 began to wane 27-days after the second dose vaccine.

These results helped demonstrate the need for additional and booster dose vaccinations.

Read the plain English summary for collaboration work on the Oxford-Astra Zeneca vaccine

Read the plain English summary for collaboration on vaccine waning in adolescents